Research graph
References from Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation. Local targets link to admitted publications; unresolved targets remain external evidence.
Current and future treatment strategies in chronic lymphocytic leukemia
10.1186/s13045-021-01054-w · 2021 · External reference
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
10.1038/s41375-019-0602-x · 2020 · External reference
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(18)30788-5 · 2019 · External reference
Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia
10.1056/nejmoa1817073 · 2019 · External reference
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
10.1056/nejmoa1812836 · 2018 · External reference
First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis
10.1002/hem3.74 · 2024 · External reference
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
10.1080/10428194.2018.1554862 · 2019 · External reference
Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma receiving ibrutinib for ≥5 years in the RESONATE-2 study
10.3390/cancers15020507 · 2023 · External reference
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
10.1182/bloodadvances.2020003423 · 2021 · External reference
Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials
10.1200/jco.2023.41.16_suppl.7538 · 2023 · External reference
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
10.1182/blood-2017-09-806398 · 2018 · External reference
A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome
10.1002/ajh.24564 · 2016 · External reference
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma
10.1080/17474086.2020.1800451 · 2020 · External reference
Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from Large Real-World Cohorts
2022 · External reference
Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib
2017 · External reference
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: methodological recommendations from Oncology Case Studies
10.1002/cpt.2453 · 2022 · External reference
Validation of real-world data-based endpoint measures of cancer treatment outcomes
2021 · External reference
Unresolved reference
2023 · External reference
P621: real-world dosing patterns and time to next treatment for previously untreated patients with CLL/SLL with or without ibrutinib dose reduction following an adverse event
2023 · External reference
Real-world persistence and time to next treatment with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma including patients at high risk for atrial fibrillation or stroke
10.1016/j.clml.2022.07.004 · 2022 · External reference
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
10.1080/03007995.2020.1835851 · 2020 · External reference
Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
10.1002/cam4.2268 · 2019 · External reference
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
10.1182/blood-2018-06-860593 · 2018 · External reference
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
10.1002/ajh.26367 · 2021 · External reference
Managing ibrutinib-intolerant patients with B-cell malignancies
10.1093/oncolo/oyac260 · 2023 · External reference
Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice
2021 · External reference
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
10.1182/blood-2018-11-846808 · 2019 · External reference
Unresolved reference
2022 · External reference
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
10.1016/s1470-2045(21)00455-1 · 2021 · External reference
Majic: a phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
10.1182/blood-2021-148155 · 2021 · External reference
Ibrutinib and venetoclax for first-line treatment of CLL
10.1056/nejmoa1900574 · 2019 · External reference
Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses
10.1016/j.jclinepi.2016.04.014 · 2016 · External reference
Using big data to emulate a target trial when a randomized trial is not available
10.1093/aje/kwv254 · 2016 · External reference
Target trial emulation
2020 · External reference
Marginal structural models and causal inference in epidemiology
10.1097/00001648-200009000-00011 · 2000 · External reference
Comparison of dynamic treatment regimes via inverse probability weighting
10.1111/j.1742-7843.2006.pto_329.x · 2006 · External reference
Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes
10.1002/pds.3253 · 2012 · External reference
Relation of pooled logistic regression to time dependent cox regression analysis: the Framingham heart study
10.1002/sim.4780091214 · 1990 · External reference
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study
10.1111/bjh.14540 · 2018 · External reference
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
10.3324/haematol.2016.147900 · 2016 · External reference
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
10.1200/jco.2012.42.7906 · 2013 · External reference
How I manage CLL with venetoclax-based treatments
10.1182/blood.2019002841 · 2020 · External reference
Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia
10.2217/ijh-2020-0010 · 2020 · External reference
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax
10.1080/03007995.2021.1929894 · 2021 · External reference
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
10.1182/blood-2016-12-737346 · 2017 · External reference
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
10.3324/haematol.2018.192328 · 2018 · External reference
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
10.1200/jco.2009.26.3087 · 2010 · External reference
Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia
10.2147/ppa.s417180 · 2023 · External reference
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
10.1182/bloodadvances.2022008325 · 2022 · External reference
Interventions to prevent potentially avoidable hospitalizations: a mixed methods systematic review
10.3389/fpubh.2022.898359 · 2022 · External reference
Study of low dose ibrutinib use in a community-based oncology practice
10.1182/blood-2020-141650 · 2020 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2023 · External reference
